Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1994-01-07
1997-12-23
Criares, Theodore J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514378, 514379, 514521, A61K 3142, A61K 31175
Patent
active
057008230
ABSTRACT:
Method for treating a patient inflicted with a cell proliferation disorder, such as a cancer, characterized by inappropriate PDGF-R activity. The method involves the step of administering to the patient a therapeutically effective amount of a composition described in application.
REFERENCES:
patent: 4284786 (1981-08-01), Kammerer et al.
patent: 4351841 (1982-09-01), Kammerer et al.
patent: 5217999 (1993-06-01), Levitzki et al.
patent: 5532259 (1996-07-01), Bartlett et al.
patent: 5547971 (1996-08-01), Weithmann et al.
Andrews et al., J. Veterinary Med. Assoc. 202(2):229-249 (1993).
Bartlett et al., Agents and Actions, 32:10-21 (1991).
Baselga et al., J. National Cancer Institute 85:1327-1332 (1993).
Baudy et al., J. Med. Chem., 36:331-342 (1993).
Bilder et al., Am. J. Physiol. 260(Cell Physiol.29):C721-C730 (1991).
Birchall and Harney, Chem. Abstract 88:535 (1978).
Bryckaert et al., Experimental Cell Research 199:255-261 (1992).
Bustelo and Barbacid, Science 256:1196-1199 (1992).
Caraglia et al., Cancer Immunol. Immunotherapy 37:150-156 (1993).
Carboni et al., J. Am. Chem. Soc., 80:2838-2840 (1958).
Chen and Okayama, BioTechniques, 6:632-638 (1988).
Dati et al., Oncogene 5:1001-1006 (1990).
Decker and Lohmann-Matthes, J. Immunol. Methods, 15:61-69 (1988).
Ehrlich and Bogert, J. Org. Chem., 12:522-534 (1947).
Ferris et al., J. Org. Chem. 44:173-178 (1979).
Floege et al., Kidney International, 43S:47-54 (1993).
Fry, et al. Protein Science 2:1785-1797 (1993).
Gazit et al., J. Med. Chem., 32:2344-2352 (1989).
Gazit et al., J. Med. Chem 34: 1896-1907 (1991).
Gazit et al., J. Med. Chem. 36:3556-3564 (1993).
Gottardis et al., J. Steroid Biochem. 30:311-314 (1988).
Gulbins et al., Science 260:822-825 (1993).
Hale et al., J. Clin. Pathol. 46:149-153 (1993).
Harris et al., New Engl. J. Medicine 327(5):319-328 (1992).
Heldin, EMBO Journal, 11:4251-4259 (1992).
Hokstra et al., Experimental Therpeutics #2455, from 84th Annual Meeting of merican Association for Cancer Research, vol. 34 (1993).
Honneger et al., Cell 51:199-209 (1987).
Issidorides and Haddadin, J. Org. Chem. 31:4067-4068 (1966).
Karameris et al., Path. Res. Pract. 189:133-137 (1993).
Koenders et al., Breast Cancer Research and Treatment 25:21-27 (1993).
Korzeniewski and Cellewaert, J. Immunol. Methods, 64:313-320 (1983).
Lee and Salemnick, J. Org. Chem. 40:3608-3610 (1975).
Levitzki, Biochem. Pharm. 40:913-918 (1990).
Ley and Seng, Synthesis 1975:415-422.
Lyall et al., J. Bio. Chem. 264:14503-14509 (1989).
Marshall, E., Science 259:618-621 (1993).
Mattar et al. FEBS 334:161-164 (1993).
Mosmann, J. Immunol. Methods 65:55-63 (1983).
Muller et al., Mol. Cell. Biol. 11:1785-1792 (1991).
Ohmichi et al., Biochemstry 32:4650-4658 (1993).
Osborne et al., Cancer Research 45:584 (1985).
Osherov et al., J. Biol. Chem. 268:11134-11142 (1993).
Osherov et al., J. Cell Biochem. 517A:237 (1993).
Ozzello and Sordat, Europ. J. Cancer 16:553-559 (1980).
Patterson et al., J. Med. Chem. 35:507-510 (1992).
Peterson and Barnes, The Prostate 22:335-345 (1993).
Piggott et al., Brit. J. of Neurosurgery 7:261-265 (1993).
Plate et al., Laboratory Investigation, 67:529-534 (1992).
Pollack et al. J. Neurosurg. 73:106-112 (1990).
Ren et al., Science 259:1157-1161 (1993).
Rendu et al., Biochemical Pharmacology 44:881-888 (1992).
Ross, Nature 362:801-809 (1993).
Rusch et al. Cancer Research 53:2379-2385 (1993).
Rygaard and Povlsen, Acta path. microbiol. scand. 77:758-760 (1969).
Schornagel et al., Biochem. Pharm. 33:3251-3255 (1984).
Scott et al., J. Biological Chem. 22:14300-14305 (1991).
Seibert et al., Cancer Research 43:2223-2239 (1983).
Shafie and Grantham, J. National Cancer Institute 67:51-56 (1981).
Skehan et al., J. Natl. Cancer Inst., 82:1107-1112 (1990).
Talmadge and Twardzik, Agents and Actions, 35S:135-141 (1991).
Ueno et al., Science, 252:844-848 (1991).
Wada et al., Oncogene 5:489-495 (1990).
Warri et al., Int. J. Cancer 49:616-623 (1991).
Yaish et al., Science 242:933-935 (1988).
Yoneda et al., Cancer Research 51:4430-4435 (1991).
Zeillinger et al., Clin. Biochem. 26:221-227 (1993).
Bristol Laboratories Oncology Products, "VePesid (Etoposide) For Injection and Capsules," Dec. 1992.
Kaur, "Tyrphostin induced growth inhibition: correlation with effect on p210.sup.bcr-abl autokinase activity in K562 chronic myelogenous leukemia," Anti-Cancer Drugs 5:213-222 (1994).
Kovalenko et al., "Selective Platelet-derived Growth Factor Receptor Kinase Blockers Reverse sis-Transformation," Cancer Research 54:6106-6114 (1994).
Mattar et al., "Effects of leflunomides active metabolite, A771726, on signal transduction pathways necessary for proliferation," Immunobiology 186(1-2):43 (1992) (abstract).
Bajor Tamas
Gazit Aviv
Haimichael Janis
Hirth Klaus Peter
Keri Gyorgy
Biosignal L.T.D.
Criares Theodore J.
Max-Planck-Gesellschaft zur Forderung der Wissenschaften e.v.
Sugen Inc.
Yissum Research Development Company, Hebrew University of Jerusa
LandOfFree
Treatment of platelet derived growth factor related disorders su does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of platelet derived growth factor related disorders su, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of platelet derived growth factor related disorders su will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1803087